This article is more than 5 years old. Information may no longer be current.

Alcon posts 17.9% rise in second quarter sales

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

HUENENBERG, Switzerland — Alcon reported global sales of $1.74 billion for the second quarter, an increase of 17.9% compared with global sales for the second quarter of 2007, or 11.2% excluding the impact of foreign exchange fluctuations, the company announced in a press release.

Net earnings for the second quarter rose 26.3% to $566.4 million, or $1.88 per diluted share, compared with $448.4 million, or $1.48 per diluted share, for the second quarter of last year.

Second quarter pharmaceutical sales rose 17.6%, or 12.1% on a constant currency basis, to $745.1 million, according to the release.

Glaucoma product sales increased 26.9% and were led by higher global sales of Travatan (travoprost) and Azopt (brinzolamide), as well as continued market share growth of DuoTrav (travoprost 0.004%, timolol 0.5%) outside the United States and the impact of the launch of Travatan Z (travoprost 0.004%) in Japan.

Infection and inflammation products increased 12.1% as a result of market share gains by Vigamox (moxifloxacin 0.5%) in the United States and growth of TobraDex (tobramycin-dexamethasone) abroad., the release said.

Allergy product sales, including Patanol (olopatadine hydrochloride 0.1%) and Pataday (olopatadine hydrochloride 0.2%), rose 5.3% despite a mild allergy season in the United States, according to the release.

Second quarter surgical sales increased 21.6%, or 13.1% on a constant currency basis, to $768.7 million. Specifically, IOL sales rose 23.5% to $288.6 million, led by the global performance of AcrySof IQ lenses and strong sales of advanced technology lenses, which rose 52% to $50.9 million for the quarter. The company attributed the increase to strong sales growth for its AcrySof toric and the AcrySof ReSTOR aspheric IOLs.

Cataract and vitrectomy product sales rose 15.6% to $449.5 million for the quarter. Refractive revenue increased 215.5% to $30.6 million, principally due to revenues generated by the WaveLight Allegretto refractive laser, according to the release.

Consumer eye care sales increased 7.8%, or 2.2% on a constant currency basis, to $221.4 million, led by a 4.6% increase in contact lens disinfectant sales.

Alcon expects full-year sales to total between $6.46 billion and $6.51 billion, for diluted earnings per share of between $6.48 and $6.54, according the release.